Bioengineering News and Research

RSS

Clockwork PCR including sample prep

Analysis and diagnosis in a chip format are coming of age, but their practical application has been limited because until now, the sample usually had to be prepared separately and on a nonminiaturized scale.

6 May 2008

New concept sends medical images via cellular phones

A process to transmit medical images via cellular phones that has been developed by a Hebrew University of Jerusalem researcher has the potential to provide sophisticated radiological diagnoses and treatment to the majority of the world's population lacking access to such technology.

29 Apr 2008

New research suggests hypertonic, hyperviscous fluids may be better treatment for severe blood loss

Intravenous administration of isotonic fluids is the standard emergency treatment in the U.S. for patients with severe blood loss, but UC San Diego bioengineering researchers have reported improved resuscitation with a radically different approach. Building on earlier studies in humans that have shown benefits of intravenous fluids that are eight times saltier than normal saline, the researchers combined hypertonic saline with viscosity enhancers that thicken blood.

29 Apr 2008

Second annual Johns Hopkins NanoBio Symposium to focus on cancer

An estimated 600 experts on nanobiotechnology-a science that develops tools and machinery at the scale of one-billionth of a meter-are expected to attend the second annual Johns Hopkins NanoBio Symposium, May 1-2, 2008.

22 Apr 2008

Discovery of process behind heart muscle contraction

Researchers from the University of Pittsburgh and the University of Chicago were able to control heart muscle function in a new way after discovering the previously unknown role of two enzymes in heart muscle contraction, as detailed in the April 11 cover story of the Journal of Biological Chemistry.

10 Apr 2008

Femtogram-level chemical measurements now possible

Finding a simple and convenient technique that combines nanoscale structural measurements and chemical identification has been an elusive goal.

31 Mar 2008

Anticancer siRNA therapy advances, thanks to nanoparticles

Small pieces of nucleic acid, known as siRNAs (short interfering RNAs), can turn off the production of specific proteins, a property that makes them one of the more promising new classes of anticancer drugs in development. Indeed, at least two siRNA-based anticancer therapies, both delivered to tumors in nanoparticles, have begun human clinical trials. Now, three new reports highlight the progress that researchers are making in developing broadly applicable, nanoparticle-enabled siRNA anticancer therapeutics.

28 Mar 2008

Spit in a cup to replace needle pricks

One day soon patients may spit in a cup, instead of bracing for a needle prick, when being tested for cancer, heart disease or diabetes.

26 Mar 2008

Researchers discover how stealthy HIV protein gets into cells

Scientists have known for more than a decade that a protein associated with the HIV virus is good at crossing cell membranes, but they didn't know how it worked.

18 Mar 2008

Peptoids as new class of antibiotic drugs

Drug-resistant bacterial infections are a growing concern, and much research has been devoted to finding new classes of antibiotics to fight them.

10 Mar 2008

Clearer understanding on how allergy symptoms are triggered

A team of Penn State University researchers is the first to demonstrate that lipid molecules in cell membranes participate in mammals' reactions to allergens in a living cell.

10 Mar 2008

Adolescents at risk of developing a substance-use disorder have deficits in frontal brain activation

Children and adolescents at high risk for developing a substance-use disorder (SUD) tend to show deficits in executive cognitive function (ECF).

6 Mar 2008

Massive brain imaging project awarded Keck Foundation grant

Tantalizing treasures of neural knowledge that lie deep in the brain of the common fruit fly are one step closer to being laid bare, now that a team of six Stanford researchers has been awarded a $1.3 million medical research grant by the W. M. Keck Foundation.

4 Feb 2008

Novel wound-healing peptide gel

First-String Research, Inc. (FSR), a spin-off biotechnology company from the Medical University of South Carolina (MUSC), has begun the human clinical trial process for its unique, wound-healing peptide gel.

4 Feb 2008

MUSC spin-off to test wound-healing peptide gel

30 Jan 2008

New method enables design, production of extremely novel drugs

A new chemical synthesis method based on a catalyst worth many times the price of gold and providing a far more efficient and economical method than traditional ones for designing and manufacturing extremely novel pharmaceutical compounds is described by its University at Buffalo developers in a review article in the current issue of Nature.

24 Jan 2008

Cheaper drugs now closer to realization with new DropArray technology

A standard laboratory tool for measuring pharmacological activity of biological substances and performing other related tests may soon be replaced by a new miniaturized bioassay that will be faster, cheaper and more efficient for scientists to use, with new technology developed by Singapore's Institute of Bioengineering and Nanotechnology (IBN).

17 Dec 2007

Short pulses of low-energy laser light create better medical images

Detection and treatment of tumours, diseased blood vessels and other soft-tissue conditions could be significantly improved, thanks to an innovative imaging system being developed that uses both light and sound.

13 Dec 2007

Biodegradable polymers with neurotransmitters promote nerve regrowth

Research reported December 11 in the journal Advanced Materials describes a potentially promising strategy for encouraging the regeneration of damaged central nervous system cells known as neurons.

12 Dec 2007

Re-engineered Gleevec reduces heart risks

Using a new bottom-up approach for rational drug design, researchers at Rice University and the University of Texas M. D. Anderson Cancer Center have reengineered the powerful anticancer drug imatinib - best known by its brand name Gleevec - to more specifically target one type of cancer while potentially curbing a rare life-threatening cardiotoxic side effect.

4 Dec 2007